The development of an M antibody capture ELISA for rubella IgM

Related Experiment Video

Updated: Jul 31, 2026

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

K Bellamy, S A Rousseau, P S Gardner

    Journal of Virological Methods
    |November 1, 1986
    PubMed

    An M antibody capture enzyme-linked immunosorbent assay for rubella IgM was developed. The enzyme label was prepared from a monoclonal antibody raised against rubella haemagglutinin (Tedder et al., 1982). Paired sera from acute rubella infections and vaccines as well as sera from blood donors, antenatal patients and patients whose sera contained rheumatoid factor and patients with acute non-rubella infections were tested by this method.

    More Related Videos

    Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae06:04

    Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

    Published on: February 24, 2023

    A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses05:22

    A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses

    Published on: November 4, 2025

    Related Concept Videos

    Enzyme-Linked Immunosorbent Assay01:33

    Enzyme-Linked Immunosorbent Assay

    In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
    There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or quantified.
    Development of Immunocompetence01:22

    Development of Immunocompetence

    The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
    The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
    Subsequent T...